The Moat Index
Compare moats, side by side.
Two to four companies, scored on the same five investor questions from their SEC filings — so the comparison is apples to apples. The method is fully public.
OMER · Healthcare · No moat
Doesn't clear the bar
The businessTrend component abstained: Fewer than two aligned fiscal years of revenue and diluted EPS are available; the filing history does not contain a measurable trend. The other four 20% weights were renormalized over the scored 80%.
HSCS · Healthcare · No moat
Doesn't clear the bar
The returnsOnCapital component abstained: Not enough years of ROIC data to score returns on capital. The other four 20% weights were renormalized over the scored 80%.
| Measure | BDX | OMER | CELZ | HSCS |
|---|---|---|---|---|
| Moat Score (0–100) | 38 (highest) | 38 (highest) | 38 (highest) | 38 (highest) |
| Methodology version | moat-index@3.0.0 | moat-index@3.0.0 | moat-index@3.0.0 | moat-index@3.0.0 |
| Business trend | 49 (highest) | — | 20 | 20 |
| Pricing power | 76 | 100 (highest) | 70 | 79 |
| Returns on capital | 0 (highest) | 0 (highest) | 0 (highest) | — |
| Balance-sheet safety | 10 | 28 | 55 (highest) | 28 |
| Capital discipline | 54 (highest) | 24 | 44 | 24 |
| Price vs. high estimate | 21% below high estimate | No price data | No price data | No price data |
| Market cap | $44.6B | $702M | $3M | $7.6M |
| Moat tier | No moat | No moat | No moat | No moat |
| Filings as of | FY2025 | FY2025 | FY2025 | FY2026 |